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 ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
curcumin is an effective treatment for Major Depressive Disorder (MDD). 
STUDY DESIGN: A systematic review of three peer-reviewed studies published between 2014 
and 2017. 
DATA SOURCES: Two of the studies were randomized, double-blind, and placebo controlled. 
The third study was a randomized controlled trial. All three studies were chosen due to relevance 
to the clinical question and if they included patient oriented outcomes. The studies were found 
using PubMed. 
OUTCOMES MEASURED: The outcomes of the studies were measured using self-report scales 
on each patient’s mood. The scales used were the Inventory of Depressive Symptomatology self-
rated version (IDS-SR30) and the Hamilton Depression Rating Scale, 17-item version (HAM-
D17). 
RESULTS: The first Lopresti et al. article2 found statistically significant positive changes in 
symptoms for patients with MDD, the sample size was not very large, which makes the study not 
very generalizable. The Sanmukhani study7 found that curcumin was as effective as fluoxetine 
during the range of the study, but the study only lasted six weeks. Finally, Lopresti’s second 
published study3 found that there was not statistically significant data to support curcumin as a 
treatment for MDD. 
CONCLUSIONS: The results of these three studies vary, showing that curcumin has the 
potential to be beneficial. However, further research is needed that includes larger sample sizes 
and longer trial durations. 
KEY WORDS: Major Depressive Disorder, Curcumin, Turmeric 
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INTRODUCTION 
Major Depressive Disorder (MDD) is a prevalent condition in the mental health field that 
can severely impact a person’s ability to function in their everyday life. Diagnostic criteria define 
MDD as having at least five symptoms of depression over the period of two weeks. Symptoms 
can include depressed mood, lack of interest in activities you previously enjoyed, weight change, 
observable slowing down of movement, fatigue, feelings of worthlessness or guilt, decreased 
ability to concentrate, and suicidal thoughts.1 MDD has the potential to overwhelm and overtake 
a person’s life, without proper intervention. While treatment options have come a long way over 
the years, many people struggle to find the right combination of medications, lifestyle changes, 
and talk therapies to help improve mood.  
	 MDD is astonishingly common. It is estimated that 16.2 million adults in the United 
Sates had at least one major depressive episode.2 This means that approximately 6.7% of all 
adults in the United States have suffered from the effects of depression.3 This statistic does not 
include the number of children and adolescents who experience MDD, which would undoubtedly 
greatly increase the percentage of Americans impacted by depression. According to the National 
Institute of Health, an estimated 3.1 adolescents from the ages of 12-17 also suffer from MDD.3   
With so many millions of people needing help with MDD, it is unsurprising that the 
economic cost is also great. It is estimated that the total economic cost of MDD is approximately 
$210.5 billion per year.4 It is further estimated that for every dollar spent on MDD, an additional 
$1.90 is spent on related and indirect costs.4 While a specific number of visits for MDD is 
unknown, it is estimated that there are 5.7 million health care visits with a psychiatric disorder as 
a diagnosis.5 With many therapists and psychiatrists often working out of insurance networks, 
this could be an under-reported statistic. 
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The exact cause of depression is still unknown. However, it is widely considered to be 
related to genetic and environmental conditions. According to the Mayo Clinic, factors such as 
biological differences, brain chemistry, hormones, and inherited traits can contribute to onset of 
depression.2 Because the exact cause of depression is still unknown, treatment varies in 
effectiveness in each individual. MDD is diagnosed according to the DSM-V and must include 
impairment in social, occupational, or other important areas of functioning that cannot be 
attributed to substance use or another medical condition.1 Unsurprisingly, this means that 
depression does not look the same for every individual diagnosed with the condition, further 
complicating its treatment. 
There are a variety of methods currently being used to treat the condition. Medications 
include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake 
inhibitors (SNRIs), tricyclic antidepressants, monoamine oxidase inhibitors (MAOIs), and other 
atypical antidepressants.5 In addition to medication, MDD is often treated with psychotherapy 
with a mental health clinician such as a licensed clinical social worker (LCSW), a licensed 
professional counselor (LPC), or a clinical psychologist.2    
Current treatment options are not effective for all patients and many of the medications have 
troubling side effects such as significant weight gain or increased suicidality.5 As a result, 
research continues to search for effective treatment outside of standard medications. Some 
researchers have found that curcumin can be effective in treating MDD with limited side effects.6 
Curcumin, also known as turmeric, has been used as an Asian herbal remedy for depression and 
anxiety since ancient times.6 Research is now trying to determine the effectiveness of this 
method in the hopes for the most effective treatment possible. 
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OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not curcumin is an 
effective treatment for Major Depressive Disorder (MDD). 
METHODS 
 The three studies analyzed in this review were found via PubMed, using keywords major 
depressive disorder, curcumin, and turmeric. All three studies were randomized and controlled 
trials (RCT). Two of the studies were double blind. The studies examined whether or not 
curcumin can be effective in treating MDD. The population included patients that are aged 
eighteen years-old or older and have been diagnosed with major depressive disorder. The 
intervention used in the studies was high-dose curcumin extract (500mg BID). The interventions 
were compared to visually matched placebos. In one study, Curcumin was also compared to 
outcomes of treatment with another medication, 20mg of fluoxetine.6 Outcomes were measured 
by several symptoms scales, including the Inventory of Depressive Symptomatology self-rated 
version (IDS-SR30) and the Hamilton Depression Rating Scale, 17-item version (HAM-D17).  
 All of the reviewed studies were published in English and were found using keywords 
“curcumin,” “turmeric,” and “major depressive disorder.” Studies were excluded if they included 
patients under the age of eighteen. The statistics used included ANOVA, p-values, and changes 
in mean from the baseline. The specific characteristics and demographics from the three studies 
can be found in Table 1.  
OUTCOMES MEASURED 
 The outcomes measured varied by each study, but all three were patient oriented 
(POEMS). Sanmukhani et al.6 measured improvements in depressive symptoms through the use 
of the Hamilton Depression Rating Scale, 17-item version (HAM-D17). In the Lopresti and   
	Hoptman, Curcumin as Treatment for MDD   4 
 
Table 1: Demographics and Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(yrs
) 
Inclusion Criteria Exclusion Criteria W
/D 
Interven-
tions 
Lop-
resti, 
2017  
(1) 
Double 
blind 
RCT 
111 18-
65 
Patients aged 18 to 65 
years who met the 
DSM-IV criteria for 
current MDD with an 
IDS-SR30 score of 18 
or greater. 
Patients with other psychiatric 
disorders, a high risk of suicide, or 
other medical illnesses; were pregnant, 
lactating or intended to fall pregnant; 
had an infection or illness over the 
past month, were currently taking any 
antiplatelet or anticoagulant 
medications; or had been diagnosed 
with any coagulation disorder. 
12 high-dose 
curcumin 
extract 500 
mg BID  
VS  
Visually 
matched 
placebo 
 
 
Lop-
resti, 
2014  
(2) 
Double 
blind 
RCT 
56 18-
65 
Patients aged 18 to 65 
years who met the 
DSM-IV criteria for 
current MDD with an 
IDS-SR30 score of 14 
or greater. 
 
Patients with other psychiatric 
disorders, a high risk of suicide, or 
other medical illnesses; were pregnant, 
lactating or intended to fall pregnant; 
had an infection or illness over the 
past month, were currently taking any 
antiplatelet or anticoagulant 
medications; or had been diagnosed 
with any coagulation disorder. 
4 curcumin 
extract 500 
mg BID  
VS  
Visually 
matched 
placebo 
BID 
 
San-
muk-
hani, 
2014  
(3) 
Double 
blind 
RCT 
60 >18 Patients over 18 who 
met the DSM-IV 
criteria for MDD and 
score more than 
seven on Hamilton 
Depression Rating 
Scale, 17-item 
version (HAM-D17) 
(Hamilton, 1960). 
 
Patients with other psychiatric 
disorders, suicidal ideation, 
schizophrenia, mental retardation, 
cognitive impairment, other 
uncontrolled organic disease, 
abnormal laboratory tests, history of 
seizure disorder (other than febrile), 
unstable thyroid disorder or known 
allergy or hypersensitivity to the 
study medications; and who had 
failed to respond to at least two 
adequate antidepressant therapies in 
the past or had taken any 
antidepressant or investigational new 
drug in last 30 days or currently 
receiving psychotherapy specifically 
designed to treat depression. 
9 curcumin 
1,000 mg 
(500 mg 
BID) 
VS 
fluoxetine 
20 mg 
daily 
VS 
curcumin 
1,000 mg 
(500 mg 
BID) and 
fluoxetine 
20 mg 
daily 
 
 
 
Drummond study,7 improvements in depressive symptoms were measured with the Inventory of 
Depressive Symptomology self-rated version (IDS-SR30). The third article by Lopresti, Maes, et 
al.8 also used the IDS-SR30 to measure changes in depressive symptoms. This study also used the 
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Spielberger State-Trait Anxiety Inventory (STAI), which is a self-report tool for assessing 
anxiety.8 
RESULTS 
 This review consists of three randomized and controlled studies that measured the mean 
change from baseline on self-report scales of depressive symptoms. Two of the studies also 
included placebos. All studies included both men and women who were eighteen years or older.  
 In the study by Sanmukhani et al., sixty patients were randomized into three different 
treatment groups.6 The first group received fluoxetine (20mg) as treatment for depression and the 
second group received curcumin (1000mg). All sixty participants were diagnosed with MDD. 
The study lasted six weeks and forty-five patients completed the trial, with no significance in 
variance of dropout rate in each group.6 Nine patients did not attend a single follow-up visit, 
leaving 51 patients included in the analysis (n=17, fluoxetine; n=16, curcumin; n=18, fluoxetine 
and curcumin).6 
 The HAM-D17 scores were analyzed at the end of the second, fourth, and sixth weeks. 
Outcomes showed similar results in treatment outcomes for the treatment groups. The mean 
change in HAM-D17 scores from the baseline at the end of the trial was -14.0 for the fluoxetine 
group, -12.6 for the curcumin group, and -14.8 for the fluoxetine and curcumin combination 
group.6 With all groups showing “excellent efficacy,” the investigators found no statistical 
difference in the three treatment groups (p=0.66).6 
 There were several patients who experienced treatment emergent adverse effects 
(TEAEs). Five patients in the combination group, two patients in the fluoxetine group, and two 
patients in the curcumin group reported these effects. TEAES included gastritis, giddiness, hot 
flushes, photosensitivity, and nausea. The medications were still considered to be well-tolerated 
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because all TEAEs were mild and there was no significant difference in vital signs, physical 
examination, or laboratory tests from the baseline. The fluoxetine group and curcumin group had 
higher proportion of “excellent” tolerability than the combination group, but the difference was 
not statistically significant (P = 0.30)7. 
Table 2: Efficacy of Curcumin in Comparison with Fluoxetine in the Treatment of Major 
Depressive Disorder, as measured by mean change in baseline from HAM-D17, conducted 
by Sanmukhani et al.6 
Study: Sanmukhani et al.6 P 
Efficacy of Curcumin in comparison with 
Fluoxetine for treatment of MDD 
0.77 
 
 The results of the Lopresti and Drummond study7 was randomized, double-blind, and 
placebo-controlled. The study comprised of 160 participants, all of whom received the placebo 
for one week. Participants were excluded if they also had a psychotic disorder, bipolar disorder, 
comorbid obsessive-compulsive disorder, posttraumatic stress disorder, eating disorder, chronic 
fatigue syndrome, fibromyalgia, any substance abuse disorder, or if they had a high risk of 
suicide.7 Patients were also excluded if they suffered from medical illnesses such as diabetes, 
autoimmune issues, cardiovascular disease, hypertension, or asthma.7  
The participants were split into four trial groups: a placebo group, a low dose of 
curcumin, a high dose of curcumin, and a combination dose of curcumin and saffron. All pills 
looked identical and participants were not told which treatment they would be receiving. 111 
participants completed the 12-week study, with no statistically significant in any one group. No 
participants dropped out due to adverse side effects.7 
The results from this study were measured by mean change from the baseline reading of 
the Inventory of Depressive Symptomatology self-rated version (IDS-SR30). The researchers 
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found that the IDS levels changed for all four groups, but only for the first four weeks for the 
placebo group. The mean change from the baseline group for the placebo was -8.91 and the high-
dose curcumin was -11.72.7 This means that the difference between the placebo and curcumin is 
small, at 2.81.  While the study demonstrates a statistically significant effect treating MDD with 
curcumin per the p value, the magnitude of baseline in IDS score is not large.7 
Table 3: Efficacy of Curcumin in Comparison with Placebo in the Treatment of Major 
Depressive Disorder, as measured by mean change in baseline from IDS-SR30 conducted by 
Lopresti, Drummond7 
Study: Lopresti, Drummond7 P 
Efficacy of Curcumin in comparison with Placebo 
for treatment of MDD 
<0.001 
 
 The third study of this review was also randomized, double-blind, and placebo controlled. 
Lopresti et al.8 used the IDS-SR30 to measure change in depressive symptoms over the course of 
8 weeks. 56 individuals participated in this study, both men and women from ages 18-65 were 
included. All participants were diagnosed with MDD according to DSM-IV criteria and had a 
baseline IDS-SR30 score of less than or equal to 14.8 Participants were excluded if he or she was 
also diagnosed with a psychotic disorder, bipolar disorder, comorbid obsessive compulsive 
disorder, or posttraumatic stress disorder. Patients were also excluded if they have substance 
abuse conditions, high risk for suicide, or have certain medical conditions. Excluded medical 
conditions included diabetes, autoimmune disease, cardiovascular disease, hypertension, 
neurodegenerative disorders, chronic fatigue syndrome, fibromyalgia, were pregnant, or were 
currently breastfeeding. A participant was also excluded if he or she has suffered an infection or 
illness in the past month, were currently taking anticoagulant medications or had an 
anticoagulant disorder.8 
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 Of the 56 participants, there were four drop-outs, three from the active treatment group 
and one from the placebo treatment group. Reasons for withdrawal included an unexpected trip 
overseas, increased digestive complaints in one person in the curcumin group, and two people 
did not consistently take the medications (one from each group).8 The participant that withdrew 
had a pre-existing digestive complaint. With this exception, there were no severe adverse events 
reported and there was no significant difference in reported adverse events between the placebo 
and curcumin groups.8  
 When the full 8 weeks of treatment are taken into account, there was no statistically 
significant difference between the IDS values in the placebo and curcumin groups. However, 
ANOVA analyses revealed some differences if the data was separated into two groups: baseline 
to week 4 and weeks 4 to 8. All IDS values decreased in baseline to week 4. However, only the 
curcumin group continued to decrease in weeks 4 to 8. The placebo group did not have 
significant changes in the latter half of the study.8 The study also measured anxiety through the 
STAI questionnaire. STAI values showed the same trend as the IDS values, in that the placebo 
had no significant changes in the second half of treatment. However, when the study is looked at 
as a whole, there was not a statistical difference between treatment groups. 
Table 4: Efficacy of Curcumin in Comparison with Placebo in the Treatment of Major 
Depressive Disorder, as measured by mean change in baseline from IDS-SR30 and STAI 
anxiety measures, conducted by Lopresti et al.8 
Study: Lopresti et al.8 P 
Efficacy of Curcumin in comparison with Placebo 
for treatment of MDD 
0.189 
 
DISCUSSION  
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 Major Depressive Disorder accounts for a large portion of adults on disability in the 
United States3 and effective treatment methods can often be elusive. This selective evidence-
based medicine review aimed to explore whether or not Curcumin could be one such effective 
treatment method. The research reviewed showed some promise, especially when Lopresti et al.8 
compared their data in two halves, separating the first 4 weeks from the final 4 weeks. The other 
two studies did not conclusively disprove curcumin as an effective treatment, further showing the 
promise of this proposed intervention. Sanmukhani et al. also showed that there was no 
statistically significant difference between curcumin and the more mainstream treatment of 
Fluoxetine6 over the six-week trial. 
 One limiting factor to cost efficiency in choosing curcumin is the bioavailability and 
absorption rates. According to the NIH, curcumin has relatively poor absorption abilities and low 
bioavailability, which are both issues that would need to be addressed in mass producing 
curcumin as an insurance-covered medication.3 Overall, it was found that curcumin was well-
tolerated by all participants. Participants included men and women from ages 18-65. MDD also 
impact children and adolescents, leading to the need for further research to be applicable to all 
ages.  
Limitations 
 Sanmukhani et al.’s study did not include a placebo group, making it impossible to 
compare the trial groups to a non-active treatment group.6 Another consideration of this study is 
the small sample size as well as the duration of the study. The number of participants was less 
than 60 which makes generalizing the results difficult and potentially inaccurate. Because 
Fluoxetine, an SSRI, can take up to six weeks to observe positive changes, the short duration of 
the study may overestimate the comparative effectiveness of curcumin. While the small sample 
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size did show promise in the effectiveness of curcumin in comparison to fluoxetine, more 
research is needed. 
 The Lopresti and Drummond study also had a small sample size, limiting the significance 
of the results.7 Furthermore, this study’s trial length was relatively short, which also limited the 
study’s ability to find statistically significant results. If the study had been larger and longer, it 
might have yielded more fruitful results. The third study of this review, Lopresti et al.,8 also had 
a relatively small population size. However, the longer length of the study yielded more 
significant results. Furthermore, both Lopresti studies reported that the participants in the trial 
mainly consisted of individuals who have had multiple depressive episodes. This could indicate 
that the patients are treatment resistant. Therefore, further research on individuals closer to initial 
onset of symptoms may see more promising results. Overall, all three studies found that further 
research is warranted as their limited initial results were promising in supporting the use of 
Curcumin in treatment of MDD.  
CONCLUSION 
 The results of the three reviewed studies were inconclusive as to whether or not curcumin 
is an effective treatment for Major Depressive Disorder. Sanmukhani et al. found that curcumin 
was no different than fluoxetine in the treatment of MDD.6 The other two studies found that 
curcumin was not different enough from the placebo to be statistically significant. However, 
curcumin cannot be ruled out as an effective treatment for MDD because the insignificant 
differences could be attributed to study length and size. Therefore, it is important to continue 
research into the efficacy of Curcumin for the treatment of Major Depressive Disorder.
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